Neratinib Lowers Recurrence in High-Risk HER2+ Breast CancerNeratinib Lowers Recurrence in High-Risk HER2+ Breast Cancer

Dr Lidia Schapira gives the take-home messages from breast cancer sessions of ASCO 2015, including top studies in HER2+ and HR+ disease, and new findings for managing side effects of treatment. Medscape Oncology

Source: Medscape Hematology-Oncology Headlines - June 15, 2015 Category: Cancer & Oncology Tags: Hematology-Oncology Viewpoint Source Type: news